Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis

Journal of Gastroenterology

Volumn 44, Issue 6, 2009, Pages 630-634

  Azemoto, Nobuaki ^a   Abe, Masanori ^a   Murata, Yosuke ^a   Hiasa, Yoichi ^a   Hamada, Maho ^a   Matsuura, Bunzo ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Glutamyl transpeptidase; Primary biliary cirrhosis; Symptoms; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; BILIRUBIN; CHOLINESTERASE; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; M2 ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD CHEMISTRY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INCIDENCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CHOLAGOGUES AND CHOLERETICS; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 67449108380     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0051-9     Document Type: Article

References (23)

1. Kaplan MM. Primary biliary cirrhosis. N Engl J Med. 1996;335:1570-80.
2. Abe M, Onji M. Natural history of primary biliary cirrhosis. Hepatol Res. 2008;38:639-45.
3. Poupon RE, Balkau B, Eschwège E, Poupon R, UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991;324:1548-54.
4. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994;19:1149-56.
5. Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995;22:759-66.
6. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology. 1999;29:644-7.
7. Poupon RE, Lindor KD, Parés A, Chazouilleres O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol. 2003;39:12-6.
8. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 2000;32:1196-9.
9. van Hoogstraten HJ, Hansen BE, van Buuren HR, ten Kate FJ, van Berge-Henegouwen GP, Schalm SW. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group. J Hepatol. 1999;31:256-62.
10. ter Borg PC, Schalm SW, Hansen BE, van Buuren HR, Dutch PBC Study Group. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006;101:2044-50.
11. Corpechot C, Carrat F, Bahr A, Chrétien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenrology. 2005;128:297-303.
12. Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871-7.
13. Parés A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715-20.
14. Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology. 1990;98:1567-71.
15. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: Survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol. 1994;20:707-13.
16. Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: A study of its natural history and prognosis. Am J Gastroenterol. 1999;94:47-53.
17. Nyberg A, Lööf L. Primary biliary cirrhosis: Clinical features and outcome, with special reference to asymptomatic disease. Scand J Gastroenterol. 1989;24:57-64.
18. Beswick DR, Klatskin G, Boyer JL. Asymptomatic primary biliary cirrhosis. A progress report on long-term follow-up and natural history. Gastroenterology. 1985;89:267-71.
19. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med. 1967;60:1257-60.
20. Angulo P, Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Kamath PS, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999;19:115-21.
21. Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology. 2002;122:652-8.
22. Angulo P, Jorgensen RA, Lindor KD. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: Is a double dosage worthwhile? Am J Gastroenterol. 2001;96:3152-7.
23. Iwasaki S, Ohira H, Nishiguchi S, Zeniya M, Kaneko S, Onji M, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res. 2008;38:557-64.